Related Experiment Videos
Steatohepatitis in obese individuals
Wael I Youssef1, Arthur J McCullough
1Division of Gastroenterology, The Robert Schwartz Center for Metabolism and Nutrition at Metro-Health Medical Center, Case Western Reserve University, Cleveland, OH 44109, USA.
Best Practice & Research. Clinical Gastroenterology
|October 31, 2002
Summary
Nonalcoholic steatohepatitis (NASH) is a severe liver disease increasingly common in obese individuals and those with type II diabetes. Weight loss and managing comorbidities are key treatments, though new therapies are under investigation.
Area of Science:
- Hepatology
- Gastroenterology
- Metabolic Diseases
Background:
- Nonalcoholic steatohepatitis (NASH) is the advanced stage of nonalcoholic fatty liver disease (NAFLD).
- It is a leading cause of chronic liver disease in developed nations, affecting 3% of the general population and 20-40% of obese individuals.
- NASH prevalence is rising due to increasing rates of obesity and type II diabetes mellitus.
Purpose of the Study:
- To highlight the progressive nature of NASH, characterized by fibrosis, cirrhosis, and potential liver-related mortality.
- To emphasize the need for improved therapeutic strategies for NASH, particularly in obese patients.
- To underscore the importance of understanding NASH pathophysiology for developing targeted treatments.
Main Methods:
- Review of current understanding of NASH prevalence, risk factors, and clinical significance.
- Analysis of established and emerging treatment modalities for NASH.
- Discussion of the impact of weight loss and comorbidity management on NASH outcomes.
Main Results:
- NASH is a progressive fibrotic disease with a significant risk of cirrhosis (25%) and liver-related death (10%) over 10 years.
- A 10% decrease in body weight can lead to histological and laboratory improvements in NASH patients.
- Bariatric surgery is a viable option for select patients.
- Pharmacological therapies are under investigation but currently unproven.
Conclusions:
- Effective management of NASH involves addressing obesity and associated comorbidities like diabetes and hyperlipidemia.
- Further research into the pathophysiology of NASH in obese patients is crucial for developing more effective therapies.
- Early recognition and intervention, including lifestyle modifications and potentially surgery, are vital for managing NASH progression.